The U.S. biosimilars market runs on a quiet but powerful engine: user-fee agreements that fund much of the Food and Drug Administration’s (FDA) review work. The current framework for biosimilars, known as the Biosimilar User Fee Act (BsUFA), was most recently reauthorized as part of the FDA User Fee Reauthorization Act of 2022, signed into law on September 30, 2022.
Within that broader law, the FDA and industry laid out a multi‑year plan often referred to as BsUFA IV, which spans fiscal years up to and including 2027 and sets the fee structure and performance goals for biosimilar product reviews. The reader’s question is narrower and more immediate: how likely is it that BsUFA IV planning for fiscal year (FY) 2028 will be formally confirmed in the next week?
Based on the limited public evidence currently available from the FDA’s own materials on BsUFA IV, there is no clear, documentable indication that a formal confirmation specific to FY 2028 is scheduled or imminent in the coming week. With only one primary FDA source in hand and no independent corroboration for a near‑term decision, any precise probability estimate would be speculative rather than evidence‑based.
What we can do is clarify what BsUFA IV is, what the FDA has already committed to, and what the thin evidence tells us—and does not tell us—about the timing of any formal confirmation related to FY 2028.
What BsUFA IV Actually Covers
According to the FDA’s public materials on BsUFA IV, the current biosimilar user-fee program is structured around a multi‑year authorization period and a set set of performance goals for biosimilar application review and related activities. These materials describe:
- The period covered by the current authorization cycle
- The framework for how biosimilar user fees are assessed and used
- Performance goals and procedures for biosimilar product development and review
The FDA’s BsUFA IV documentation focuses on the existing authorization window and the agreed‑upon goals that flow from the 2022 law. The agency’s own description is the main factual anchor here. Within that framework, fiscal years are laid out as part of a defined cycle; the law signed on September 30, 2022, effectively locked in the current BsUFA phase and its goals for the duration of that window.
On that basis, the core facts are:
- BsUFA IV is an established, currently operative program under the FDA User Fee Reauthorization Act of 2022.
- The FDA has publicly described the scope and structure of BsUFA IV on its website, including its multi‑year nature.
- The program’s timelines and goals are already defined for the authorized period.
None of the available FDA material, however, explicitly points to a discrete, separate “formal confirmation” event for FY 2028 that is scheduled for the coming week.
Why FY 2028 Matters for Biosimilars
The question about FY 2028 is not academic. User-fee cycles shape how quickly biosimilars reach patients and how predictable the regulatory environment is for manufacturers. The FDA’s BsUFA IV documentation makes clear that user fees support:
- The review of biosimilar biological product applications
- Biosimilar product development meetings and advice
- Infrastructure and staffing needed to meet review timelines
If FY 2028 is part of the same overarching BsUFA IV cycle, clarity around that year’s fee structure and performance goals would matter for:
- Manufacturers, who plan development and submissions years in advance
- Providers, who depend on a stable pipeline of approved biosimilars
- Patients and payers, who benefit when biosimilars are reviewed efficiently and predictably
However, the FDA’s current BsUFA IV materials, as available from the agency, speak to the overall program and its current authorization period. They do not, in the publicly accessible documentation used here, flag a specific pending decision point confined to FY 2028 that is due in the next week.
What the Evidence Shows—and What It Does Not
The only solid, event‑direct evidence in play is the FDA’s own description of BsUFA IV and the fact that the broader FDA User Fee Reauthorization Act of 2022 is already law. From that, we can say with confidence:
- The current BsUFA framework is in effect.
- Its multi‑year scope is already defined in statute and in FDA‑industry performance goal documents.
Where the evidence is thin is on the timing of any additional, FY 2028‑specific confirmation:
- There is no publicly documented FDA announcement, in the material at hand, of a scheduled decision or formal confirmation event for FY 2028 in the next week.
- Independent corroboration for any near‑term move relating specifically to BsUFA IV and FY 2028 is limited and should be monitored as new reporting or official notices appear.
Given those constraints, any attempt to assign a numerical probability (for example, “60% likely”) to a formal FY 2028 confirmation next week would not be grounded in the available record. The most defensible statement, based on what we have, is that there is no concrete, publicly documented signal pointing to such an event in that timeframe.
Implications for Key Stakeholders
Even with limited visibility into next week’s calendar, the structure of BsUFA IV as described by the FDA allows some grounded observations about who is positioned where.
FDA
The FDA operates under the framework already authorized by Congress. Under BsUFA IV, as documented on fda.gov, the agency has defined performance goals and resource plans for the current cycle. That means:
- The FDA already has a legal and operational basis for biosimilar review through the BsUFA IV window.
- The agency’s near‑term biosimilar review work does not hinge on a new, separate FY 2028 confirmation this week, based on the structure described in its own materials.
Industry
Biosimilar sponsors rely on predictable user‑fee structures and review timelines. From the FDA’s BsUFA IV documentation, industry can see:
- The contours of the current user‑fee program and performance expectations.
- The multi‑year nature of the agreement, which is already embedded in the 2022 law.
What industry does not yet have, based on the evidence at hand, is a public, date‑certain confirmation that any FY 2028‑specific adjustment or extension will be locked in next week. Companies therefore must plan using the existing BsUFA IV framework and watch for new FDA or congressional signals.
Patients and Providers
For patients and clinicians, the question is whether any uncertainty around FY 2028 could slow access to biosimilars. The FDA’s own description of BsUFA IV indicates that the current program is already in force, supporting ongoing review work. That suggests:
- No immediate disruption to biosimilar review is implied by the absence of a new FY 2028 confirmation this week in the public record.
- The key risk would arise only if, over time, future user‑fee authority were allowed to lapse or remain unresolved—something not indicated by the current FDA materials.
How to Think About the Next Week
With only one primary, event‑direct source and no explicit mention of a near‑term FY 2028 decision, the analytical posture has to be cautious.
- Evidence‑based view: The FDA’s BsUFA IV documentation shows a program already authorized and operating over a defined multi‑year window. There is no clear, public sign in that material of a scheduled FY 2028‑specific confirmation in the next week.
- Uncertainty: Independent corroboration for any claim that such a move is imminent is limited. That absence of evidence is not proof that nothing will happen—but it does mean we cannot responsibly claim that a confirmation is likely on a specific short‑term timeline.
In practical terms, that means the probability of a formal BsUFA IV FY 2028 confirmation next week, as far as the public record used here is concerned, is not knowable with precision and cannot be described as high without venturing beyond the evidence.
What to Watch Next
Within the constraints of the current record, the most concrete steps for observers are straightforward:
- FDA communications: Monitor FDA’s official BsUFA IV page and Federal Register notices for any updates that mention FY 2028 explicitly.
- Congressional action: User‑fee programs ultimately rest on statute. Any move to adjust or extend BsUFA terms for FY 2028 would likely be reflected in legislative activity or public statements.
- Stakeholder briefings: The FDA often communicates with industry through public meetings or guidance documents tied to user‑fee programs. New materials referencing FY 2028 would be a meaningful signal.
Until such signals appear in the public record, the only defensible conclusion is that BsUFA IV remains the operative framework under the 2022 law, and that the likelihood of a distinct, formal FY 2028 confirmation in the coming week cannot be reliably quantified from the information currently available.
